文献速递免疫规划慢病防控与筛查

单剂四价HPV疫苗在蒙古年轻女性中六年后的免疫原性与HPV检出率

A single dose of quadrivalent human papillomavirus (HPV) vaccine is immunogenic and reduces HPV detection rates in young women in Mongolia, six years after vaccination.
PubMed 文献 · Vaccine · 2020-05-07

该回顾性配对队列研究纳入475名蒙古年轻女性,比较11-17岁接种单剂四价HPV疫苗者与未接种者的HPV检出率及中和抗体水平。结果显示疫苗靶向高危型HPV16/18检出率下降92%,接种者六年后的血清阳性率及中和抗体水平显著高于未接种者。

要点

  • 单剂四价HPV疫苗使HPV16/18检出率降低92%(95%CI 44-99%)。
  • 接种六年后约90%和58%的女性对HPV16和18仍血清阳性。
  • 非疫苗型HPV检出率两组相似,提示单剂保护具有型别特异性。

核心结论

  • 单剂四价HPV疫苗在接种六年后可降低疫苗靶向HPV型别检出率,并诱导高水平中和抗体。

研究设计与样本

  • 回顾性配对队列研究,纳入475名蒙古年轻女性(平均年龄20.4岁±1.6),其中118名接种单剂四价HPV疫苗、357名未接种。

主要发现

  • 非疫苗HPV基因型检出率在接种组为26.5%、未接种组为26.7%,两组相似。
  • 接种六年后,约90%和58%的接种女性对HPV16和18仍血清阳性,中和抗体水平分别较未接种者高5倍和2倍(p < 0.001)。

临床怎么用

  • 单剂四价HPV疫苗可能作为减少HPV16/18感染的替代策略,尤其适用于资源有限地区。

局限性

  • 本研究为观察性设计,样本量有限,免疫学分析仅基于58名参与者的亚组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Emerging observational evidence suggests a single-dose of human papillomavirus (HPV) vaccine may be protective against vaccine-targeted HPV infection and associated cervical dysplasia. We aimed to demonstrate whether a single dose of quadrivalent HPV (4vHPV) vaccine was immunogenic and reduced HPV detection rates in young women in Mongolia. We also assessed knowledge and attitudes regarding HPV and the HPV vaccine. METHODS: A retrospective paired cohort study was undertaken to evaluate the effect of a single dose of 4vHPV, given at age 11-17 years in 2012, on HPV detection rates, when compared with unvaccinated women. Real time PCR was performed on self-administered vaginal swabs for HPV detection. An immunological analysis detecting neutralising antibodies (NAb) to high-risk HPV (HRHPV) genotypes 16 and 18 was performed on sera from a subset of 58 participants. Questionnaires evaluated knowledge, attitudes and self-swab acceptability. FINDINGS: A total of 475 women (mean age 20.4 years ± 1.6) were recruited; 118 vaccinated and 357 unvaccinated women. The prevalence of vaccine-targeted HRHPV16 and 18 was reduced by 92% (95%CI 44-99%) in the vaccinated (1·1%) compared with the unvaccinated (15.4%) group. The percentage of non-vaccine HPV genotypes was similar between vaccinated (26.5%) and unvaccinated (26.7%) groups. Approximately 90% and 58% of vaccinated women remained seropositive after six years for HRHPV16 and 18, respectively, with neutralising antibody levels 5- and 2-fold higher than unvaccinated women (p < 0.001). INTERPRETATION: One dose of 4vHPV vaccine reduces vaccine-targeted HPV genotypes, six years following vaccination, with high levels of HR genotype seropositivity among young Mongolian women.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Batmunkh T, Dalmau MT, Munkhsaikhan ME, et al. A single dose of quadrivalent human papillomavirus (HPV) vaccine is immunogenic and reduces HPV detection rates in young women in Mongolia, six years after vaccination. Vaccine. 2020. PMID: 32387009. doi:10.1016/j.vaccine.2020.04.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。